T1	intervention 0 14	Bisphosphonate
T3	total-participants 233 236	953
T4	eligibility 237 292	patients with lymph node negative primary breast cancer
T5	intervention 332 335	460
T6	control 371 394	no adjuvant pamidronate
T7	control-participants 398 401	493
T8	outcome 924 942	recurrence in bone
T11	cv-bin-abs 841 843	22
T12	iv-bin-abs 869 871	20
T13	outcome 651 695	number of patients with pure bone metastases
T10	outcome 761 835	number of patients with a combination of bone and other distant metastases
T14	cv-bin-abs 700 702	35
T15	iv-bin-abs 728 730	31
T2	outcome 1081 1097	overall survival
T9	outcome 1244 1284	bone mineral density in the lumbar spine
